Analyst Conference Call Notes by William Meyers

Biotechnology Investor Aids

Celsion
CLSN

conference date: November 15, 2018 @ 8:00 AM Pacific Time

Independent NIH Analysis of Thermodox plus RFA for Liver Cancer [September 12, 2016]

RFA plus lyso-thermosensitive liposomal doxorubicin [June 10, 2016] all the details on Thermodox studies

2018
 
May 10, 2018
August 14, 2018
Nov. 15, 2018
 
2017
May 12, 2017
August 15, 2017
Nov. 14, 2017
March 27, 2018
2016
 
08/15/2016
11/10/2016
03/16/2017
 

Celsion (CLSN) is a clinical-stage biotechnology company specializing in cancer therapies. Its lead product is ThermoDox for liver cancer.

Celsion web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2018 William P. Meyers